Gilead Sciences clearly liked what it saw in the early stages of its 2019 partnership with Nurix on protein degradation drugs – it has just opted into the first of five po
Gilead has won another victory in a wide-ranging lawsuit brought against clinics, prescribers, medical labs, and pharmacies it has accused of making fraudulent reimburseme
The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market
US biotech EVOQ Therapeutics has lined up another partner for its NanoDisc immunotherapy technology, with Gilead Sciences buying into the platform in a deal valued at up to $658.5 million.<
Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of th
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough